Gastric banding and opioid cravings are increasingly recognised as a clinically important combination, with emerging evidence suggesting that bariatric surgery may heighten vulnerability to substance use disorders in certain individuals. When food intake is dramatically restricted, the brain's reward pathways — previously stimulated by eating — may seek alternative sources of stimulation, including opioids. This article explores the neurobiological mechanisms behind this link, how gastric banding may affect opioid absorption, how to recognise signs of dependence, and what NHS treatment and support options are available for those affected.

Why Gastric Banding May Increase the Risk of Opioid Cravings

Gastric banding reduces food-based reward stimulation, and in neurobiologically vulnerable individuals, the brain may seek dopamine activation through opioids instead, particularly in those with prior trauma, mood disorders, or substance use history.

Gastric banding is a form of bariatric surgery in which an adjustable silicone band is placed around the upper portion of the stomach, creating a small pouch that restricts food intake. While the procedure is effective for weight loss, some evidence suggests that bariatric surgery in general — and to a lesser extent gastric banding specifically — may, in certain individuals, contribute to an increased vulnerability to opioid cravings and substance use disorders. It is important to note that the strongest evidence for increased substance use risk after bariatric surgery relates to alcohol use disorder following Roux-en-Y gastric bypass; data specific to opioid misuse after gastric banding are more limited, and claims in this area should be understood in that context.

The proposed underlying mechanism is neurobiological. Food — particularly high-calorie, palatable food — activates the brain's reward pathways, releasing dopamine in a manner that shares features with the effects of addictive substances. When food intake is dramatically restricted following bariatric surgery, this reward stimulus is significantly reduced. For individuals who relied on food as a way of coping with stress, anxiety, or emotional distress, the reduction of that reward signal may leave the brain seeking alternative sources of stimulation.

Opioids interact with the same mesolimbic dopamine reward system. This neurochemical overlap means that individuals with pre-existing vulnerabilities — such as a history of trauma, mood disorders, or prior substance use — may be at increased risk of opioid cravings after surgery. It is important to emphasise that not all patients who undergo gastric banding will experience this, and the risk varies considerably based on individual psychological history, prior substance use, perioperative opioid exposure, and social circumstances. Careful perioperative opioid prescribing and early deprescribing are recognised as key mitigations.

Worried about interactions with other medications? Speak to one of our pharmacists →

The Link Between Bariatric Surgery and Substance Use Disorders

Some post-bariatric patients develop substance use disorders as a replacement for compulsive eating; the strongest evidence concerns alcohol misuse after gastric bypass, though opioid misuse is an emerging concern requiring pre- and post-operative psychological screening.

There is growing clinical recognition that some individuals who have undergone bariatric surgery may develop a substance use disorder after surgery, sometimes replacing compulsive eating with another addictive behaviour. This may include alcohol misuse, gambling, compulsive shopping, or, in some cases, opioid and other drug use. Research highlighted by the British Obesity and Metabolic Surgery Society (BOMSS) has identified this as a clinically significant concern, though it is important to note that the strongest and most consistent evidence concerns alcohol use disorder following Roux-en-Y gastric bypass, rather than gastric banding specifically. Evidence for opioid misuse as a post-bariatric complication is more limited and continues to emerge.

A key contributing factor is that many patients receive opioid-based analgesics in the immediate post-operative period for pain management. For vulnerable individuals, this initial exposure can be a starting point for developing a pattern of craving or dependence.

Psychological factors play a central role. Patients who have a history of:

• Trauma or adverse childhood experiences

• Depression or anxiety disorders

• Previous substance misuse

• Binge eating disorder prior to surgery

...are considered at higher risk of developing a substance use disorder after surgery. Pre-operative psychological screening, as recommended within NHS bariatric pathways (in line with NICE guidance on obesity, including CG189), is designed in part to identify these vulnerabilities. Post-operative psychological support is equally important; availability may vary locally, and patients are encouraged to ask their bariatric team what support is available to them. Integrated multidisciplinary team (MDT) care — combining bariatric, psychological, and, where needed, substance misuse input — represents best practice.

How Opioid Absorption May Change After Gastric Banding

Gastric banding causes generally modest pharmacokinetic changes compared to malabsorptive procedures, but altered gastric emptying can affect oral opioid absorption; modified-release formulations must never be crushed, and specialist pharmacy advice should be sought.

Unlike gastric bypass procedures, gastric banding does not anatomically alter the digestive tract in a way that fundamentally changes the absorptive surface of the small intestine. The band simply restricts the size of the stomach pouch, slowing the rate at which food and liquids pass through. As a result, the pharmacokinetic changes associated with opioid absorption are generally less significant following gastric banding than after malabsorptive procedures such as Roux-en-Y gastric bypass or sleeve gastrectomy, where absorption changes are better established.

Nevertheless, some changes in drug absorption can still occur. The altered gastric emptying caused by the band may affect the rate at which oral opioid formulations — such as codeine, tramadol, or oral morphine — are absorbed. Modified-release opioid preparations may be of particular concern, as their controlled-release mechanisms depend on predictable gastrointestinal transit. Disruption to this process can, in some cases, lead to unpredictable plasma drug levels. Importantly, modified-release tablets and capsules should never be crushed or split, as this destroys the release mechanism and may result in rapid drug release and toxicity.

Patients and prescribers should be aware that:

• Absorption changes after gastric banding are generally modest, but individual variation exists

• Liquid or soluble immediate-release formulations may offer more predictable absorption where clinically appropriate

• Any opioid prescription following bariatric surgery should be reviewed by a clinician or pharmacist experienced in post-bariatric care

The UK Specialist Pharmacy Service (SPS) and BOMSS provide guidance on medicines use after bariatric surgery, and these are the recommended resources for clinicians managing pain or other medication needs in this population. Individual drug Summaries of Product Characteristics (SmPCs), available via the MHRA/electronic Medicines Compendium (EMC), do not always provide specific guidance for post-bariatric patients, so specialist input is essential.

Recognising Signs of Opioid Dependence After Weight Loss Surgery

Signs of opioid dependence include using opioids beyond the prescribed period, seeking early refills, experiencing withdrawal symptoms, and feeling unable to cope without them; opioid overdose is a medical emergency requiring an immediate 999 call.

Identifying opioid dependence (also referred to as opioid use disorder) in post-bariatric patients can be challenging, partly because some symptoms overlap with common post-operative experiences such as fatigue, mood changes, and altered appetite. Nonetheless, early recognition is critical to preventing escalation and ensuring timely access to support.

Common signs of opioid dependence to be aware of include:

• Continuing to use opioid medicines beyond the prescribed period

• Requesting early prescription refills or visiting multiple healthcare providers to obtain opioids

• Using opioids for reasons other than pain relief, such as to manage anxiety or low mood

• Experiencing withdrawal symptoms (sweating, agitation, muscle aches, nausea) when opioids are not taken

• Neglecting responsibilities, relationships, or self-care in favour of obtaining or using opioids

• Feeling unable to cope without opioids, even when the original pain has resolved

Emotional and psychological signs are equally important. Patients may describe a sense of relief or calm when taking opioids that goes beyond simple pain relief, or they may feel intense cravings between doses. These experiences should be taken seriously and discussed openly with a GP or bariatric care team without fear of judgement.

It is worth noting that physical dependence (the body adapting to the presence of a drug, leading to withdrawal symptoms on stopping) is not the same as opioid use disorder (compulsive use despite harm), though both require clinical attention and are addressed in NICE guidance (CG51, CG52) and the UK clinical management guidelines (the 'Orange Book'). Post-bariatric patients prescribed opioids for legitimate pain should be monitored regularly, and any concerns about escalating use should prompt a structured clinical review.

Signs of opioid overdose require immediate emergency action. Call 999 if someone shows: slow, shallow, or stopped breathing; blue-tinged lips or fingertips; unresponsiveness or inability to be woken; or pinpoint pupils. Do not wait — this is a medical emergency.

NHS Support and Treatment Options for Post-Surgery Opioid Cravings

NHS drug and alcohol services provide opioid substitution therapy with methadone or buprenorphine, naltrexone for relapse prevention, CBT, and take-home naloxone; sublingual and injectable buprenorphine formulations are particularly suitable for post-bariatric patients.

The NHS offers a range of evidence-based treatment options for individuals experiencing opioid cravings or dependence, and these are accessible to post-bariatric patients. Treatment is typically delivered through NHS Drug and Alcohol Services (also known as substance misuse services), which can be accessed via GP referral or, in many areas, through self-referral.

Key treatment options available on the NHS include:

• Opioid substitution therapy (OST): Medicines such as methadone or buprenorphine are prescribed to reduce cravings and withdrawal symptoms, in line with NICE technology appraisal TA114. Buprenorphine is available in sublingual (under-the-tongue) and buccal formulations, which bypass the gastrointestinal tract and are therefore unaffected by any changes in gastric anatomy. A prolonged-release injectable form of buprenorphine (Buvidal, available as weekly or monthly injections) is also licensed and used within some NHS services, offering an option that avoids oral absorption issues entirely. Generic names are used here; your prescriber will advise on the most appropriate formulation for your circumstances.

• Naltrexone (oral): An opioid antagonist that blocks the euphoric effects of opioids, used as a relapse-prevention medicine after opioid detoxification (as described in NICE CG52). Oral naltrexone is the licensed form available in the UK for this indication. It is not a first-line treatment for active opioid dependence and is used under specialist supervision.

• Psychological therapies: Cognitive behavioural therapy (CBT), motivational interviewing, and trauma-focused therapies are recommended by NICE (CG51: Drug misuse — psychosocial interventions) as core components of opioid dependence treatment.

• Harm reduction — take-home naloxone: NHS drug and alcohol services can provide take-home naloxone kits and training to patients and their families or carers. Naloxone rapidly reverses opioid overdose and can be life-saving in an emergency. Ask your local service or GP about access.

• Peer support and community programmes: Organisations such as Narcotics Anonymous (NA) and SMART Recovery offer free, community-based support that complements clinical treatment.

Bariatric teams and substance misuse services do not always communicate routinely, so patients may need to advocate for integrated care. Ideally, post-bariatric patients with opioid concerns should have a care plan that involves both their bariatric team and a substance misuse specialist.

If you believe a medicine has caused an unexpected or harmful reaction, you can report this to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk or through the Yellow Card app.

When to Seek Help and Who to Contact on the NHS

Contact your GP if opioid use is escalating or difficult to control; self-referral to NHS drug and alcohol services is available in England, and Frank (0300 123 6600) offers free 24-hour confidential advice.

If you or someone you know is experiencing opioid cravings, escalating opioid use, or signs of dependence following gastric banding, it is important to seek help promptly. Early intervention significantly improves outcomes, and NHS services are non-judgemental and confidential.

Contact your GP in the first instance if:

• You are using opioids more frequently or in higher doses than prescribed

• You feel unable to stop taking opioids despite wanting to

• You are experiencing mood changes, withdrawal symptoms, or cravings

• You are concerned that a prescribed opioid is becoming difficult to manage

Your GP can refer you to local NHS drug and alcohol services, arrange a medication review, and coordinate with your bariatric team. In England, you can also self-refer to NHS drug and alcohol services without needing a GP referral — a directory of local services is available via the NHS website (www.nhs.uk) or by calling Frank (0300 123 6600), a free, confidential drugs helpline available 24 hours a day. Local drug and alcohol services can also provide take-home naloxone kits and training for you or someone close to you.

For urgent concerns — such as opioid overdose, severe withdrawal, or a mental health crisis — call 999 or attend your nearest A&E department. NHS 111 can also provide guidance outside of GP hours.

Unsure about your dosage? Our pharmacists can give you guidance →

If you think a medicine has caused a side effect or unexpected reaction, please report it to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk or using the Yellow Card app. This helps improve medicine safety for everyone.

Finally, patients awaiting or recovering from bariatric surgery are encouraged to speak openly with their bariatric team about any history of substance use or concerns about addiction. Pre- and post-operative psychological support is a recognised component of best-practice bariatric care, and raising these concerns early is a sign of strength, not weakness.

Frequently Asked Questions